Ryan Schoenfeld, PhD, is Chief Executive Officer of The Mark Foundation for Cancer Research, a philanthropic organization dedicated to transforming the prevention, diagnosis, and treatment of cancer around the world. An experienced scientific leader, Ryan oversees the Foundation’s scientific programs, investments, and operations. Ryan joined The Mark Foundation in 2018, was named Chief Scientific Officer in 2021, and was named CEO in 2022. During his tenure, Ryan has worked to establish The Mark Foundation as a leader in accelerating innovative cancer research across diverse areas of science including molecular biology, chemistry, immunology, genetics, and data science.

Prior to joining The Mark Foundation, Ryan was Senior Director of Data Sciences at Janssen Pharmaceutical Companies of Johnson & Johnson, where he built and led a large global team of data scientists who delivered high impact machine learning and AI-based solutions for a wide range of problems across all therapeutic areas. Prior to his time at J&J, Ryan was a Scientific Director at the CHDI Foundation, where he pursued therapeutics for Huntington’s disease, directing teams of global collaborators in medicinal chemistry, chemical biology, structural biology, imaging biomarkers, and stem cell research. Earlier in his career, Ryan worked for Roche Pharmaceuticals where he led medicinal chemistry and chemical biology projects across several different therapeutic areas, coordinated global research informatics initiatives, and oversaw all discovery chemistry and biology partnerships for North America.